Co-incident with the SAPK activation, treatments with CFMs over a 6-12h period stimulated activation of PARP and caspase 8, while causing a significant decline in levels of mitotic cyclin B1 in the RCC cells (Figure 3A–3D). The gene discussed is CCNB1; the disease is renal cell adenocarcinoma.